Pasithea Therapeutics Corp (KTTA): Growth-Adjusted Market Cap to Net Income
Risks for Pasithea Therapeutics (KTTA) are linked to the lack of recurring revenue and the potential failure of psychiatric developments. An upward trend in the P/E ratio serves as an indicator of stability, where 0.00 determines this parameter level. High patient loyalty at ketamine centers and strict DEA control ensure stability, while asset value is based on client flow and successes in PTSD therapy.
Analytical breakdowns for Pasithea Therapeutics (KTTA)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- company book value details:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Pasithea Therapeutics|KTTA - Long-Term Debt to Capital|Current Liabilities to Capital pasitheaclinics.com|KTTA - Company Aggregate Debts|Debts to Book Capitalization Pasithea|KTTA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Pasithea Therapeutics|Intermediate Liquidity Ratio pasitheaclinics.com
- net income and valuation ratios data:
KTTA - Net Profit|Expected Net Income Pasithea Therapeutics|KTTA - P/E Multiple|Projected Price to Earnings Ratio pasitheaclinics.com|KTTA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Pasithea|KTTA - Operating profit EBITDA|Net earnings per share (EPS TTM) Pasithea Therapeutics|KTTA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months pasitheaclinics.com|KTTA - Earnings growth in current year|Expected net earnings per share growth next year Pasithea Therapeutics
General company analysis:KTTA Pasithea Therapeutics Corp
The market value of Pasithea Therapeutics (KTTA) depends directly on the success of clinical trials for brain disorder therapies and the volume of R&D funding. By analyzing the PEG ratio, an investor compares the current P/E multiple with the earnings growth rate: a value below one signals that the asset is undervalued relative to its expansion, confirming the sustainability of the biotech's business model.
Who Pasithea Therapeutics competes with
PEG Multiple Biogen Inc (BIIB)|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Growth-Adjusted Market Cap to Net Income Regencell Corp (RGC)|Axsome Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income acadia-pharm.com ACAD|XENE (Xenon) - Price/Earnings to Growth Multiple|VKTX: Company Value to Earnings Growth Ratio|SUPN (Supernus Pharma) - PEG Multiple|CPRX: Growth-Adjusted Payback Ratio|PEG Multiple DNLI|HRMY - Price to Earnings Adjusted for Growth Rate|PEG Multiple BHVN (Biohaven)|PEG Multiple Amylyx Pharmaceuticals Inc AMLX|TRVI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|AVXL (Anavex Life Sciences) - Price/Earnings to Growth Multiple|CBLL: Company Value to Earnings Growth Ratio|PRTA (Prothena Corporation plc) - PEG Multiple|ALEC: Growth-Adjusted Payback Ratio|PEG Multiple ANNX|OMER - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neurogene Inc. NGNE|Growth-Adjusted Payback Ratio ACIU|Voyager Therapeutics, Inc. - PEG Multiple|NMRA - PEG Multiple|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio TVGN (Tevogen Bio Inc.)|ACOG (Alpha Cognition Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate cogrx.com CGTX|Price/Earnings to Growth Multiple IKT (Inhibikase Therapeutics, Inc.)|PEG Multiple Cassava Sciences Inc (SAVA)|Assertio - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio COYA (Coya Therapeutics Inc)|VistaGen Therapeutics Inc - PEG Multiple|Growth-Adjusted Market Cap to Net Income Ovid Therapeutics Inc. OVID|ABOS: PEG Multiple|Price/Earnings to Growth Multiple CervoMed, Inc.|Price/Earnings to Growth Ratio Alterity Therapeutics Ltd.|Clene Nanomedicine (CLNN) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio PepGen Inc. (PEPG)|PEG Multiple jupiterneurosciences.com (JUNS)|Relmada Therapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio ANVS (Annovis Bio Inc)|GRCE: Price/Earnings to Growth Multiple|Firefly Neuro - Company Value to Earnings Growth Ratio|KLTO: PEG Multiple|NeuroSense Therapeutics Ltd. (NRSN) - PEG Multiple|Price/Earnings to Growth Ratio Reviva Pharmaceuticals Holdings, Inc.|Growth-Adjusted P/E Ratio MTVA (MetaVia, Inc.)|PEG Multiple NRXS|HSDT - Price to Earnings Adjusted for Growth Rate|Passage Bio - Price/Earnings to Growth Multiple|PEG Multiple Neuphoria Therapeutics, Inc. NEUP|NERV - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. (ADXN) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Alzamend Neuro (ALZN)|Price/Earnings to Growth Ratio Cyclerion Therapeutics Inc.|Protagenic - Market Cap to Earnings and Growth Ratio|PEG Multiple CRGT|PEG Multiple Avenue Therapeutics Inc. (ATXI)|Price/Earnings to Growth Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Growth-Adjusted Market Cap to Net Income Cara Therapeutics Inc (CARA)|Chromocell Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income Eliem Therapeutics ELYM|ITCI (intracellulartherapies.com) - Price/Earnings to Growth Multiple|LBPH: Company Value to Earnings Growth Ratio|MRNS (Marinus) - PEG Multiple|NKGN: Growth-Adjusted Payback Ratio|PEG Multiple NRBO|SAGE - Price to Earnings Adjusted for Growth Rate|PEG Multiple SNPX (Synaptogenix)|PEG Multiple Trevena Inc. TRVN|VIGL: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio WENA (Anew Medical Inc.)|CERE (Cerevel Therapeutics) - Price/Earnings to Growth Multiple
